FDA recall D-0251-2026

Imprimis NJOF, LLC · Class II · drug

Product

Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.

Reason for recall

Presence of particulate matter - Glass like particles.

Distribution

U.S Nationwide

Key facts

Status
Ongoing
Initiation date
2025-12-18
Report date
2026-01-14
Voluntary/Mandated
Voluntary: Firm initiated
Location
Ledgewood, NJ, United States

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0251-2026